In 2015, various compounds targeted at the NCp7 zinc fingers have been developed, but only one, HPH116 (cGMP micronized azodicarbonamide), has entered clinical trials so far. and disposes of pharmacological data alowing clinical phase II

From Bruce E. Torbett • David S. Goodsell Douglas • D. Richman

The Future of HIV-1 Therapeutics     

Library of Congress Control Number: 2015937951 Springer Cham Heidelberg New York Dordrecht London © Springer International Publishing Switzerland 2015

Compounds Zinc Ejectors: sole Azodicarbonamide is safe enough for drug ability








On March 16, 2015 patent EU 09151596.5 (notification following Rules 71.3 CE) was granted and validated.

>> More


H-Phar SA is involved in Partnering for Vaccine Emerging Markets

Method of using zinc finger inhibitors to target and destabilize zinc fingers represents a new method of fighting HIV. Other viruses such as SARS, polio, Ebola, measles, human coxsackie, Dengue, rabies, human hepatitis, human parainfluenza and human respiratory syncytical have similar zinc finger motifs and could potentially benefit from zinc finger inhibitor technology

>> More
Breaking news 2015

2015: 2nd Meeting of ACP Ministers of Health, 25 February 2015, Brussels

Division research of H-Phar SA Pharmaceuticals worked intensively in collaboration with all African Caribbean Pacific countries

representatives to establish the EU/ACP/WHO

Renewed Partnership in strengthening pharmaceutical systems and improving access to quality medicines in 15 African countries, in the post-2015 Development Agenda.


>> More


More Click







H-Phar™ and the H-Phar logo are registred trademarks of H-Phar Company™